CHM chimeric therapeutics limited

https://www.europeanpharmaceuticalreview.com/news/191125/long-ter...

  1. 916 Posts.
    lightbulb Created with Sketch. 579
    https://www.europeanpharmaceuticalreview.com/news/191125/long-term-findings-from-car-nk-cell-therapy-trial-revealed/

    "For the trial, cord blood units that were cryopreserved within 24 hours of collection and those with a low nucleated red blood cell content were associated with markedly better outcomes, according to the data."

    For instance, “CAR NK cells generated from these units resulted in a one-year PFS rate of 69 percent and an overall survival rate of 94 percent. This was compared to five percent and 48 percent, respectively, from those units with higher nucleated red blood cell content or longer collection-to-cryopreservation times.”

    Author Dr Katy Rezvani, PhD, professor of Stem Cell Transplantation & Cellular Therapy at the University of Texas M. D. Anderson Cancer Center.

    Useful information for Dr Maiti as he starts enrolling patients.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $28.14K 7.037M

Buyers (Bids)

No. Vol. Price($)
1 243067 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 14771167 22
View Market Depth
Last trade - 15.39pm 20/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.